Platelet glycoprotein IIb/IIIa receptor inhibitors: is their future as bright as their past?
Leesar
Massoud A
MA
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation; D002317:Cardiovascular Agents / Q000008:administration & dosage; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications* / Q000401:mortality / Q000628:therapy; D054855:Drug-Eluting Stents; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012107:Research Design; D018570:Risk Assessment; D020123:Sirolimus / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
D002317:Cardiovascular Agents; D007004:Hypoglycemic Agents; D007328:Insulin; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D020123:Sirolimus